Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed to treat anxiety and depression, yet they paradoxically increase anxiety during initial treatment. Acute administration of these drugs prior to learning can also enhance Pavlovian cued fear conditioning. This potentiation has been previously reported to depend upon the bed nucleus of the stria terminalis (BNST). Here, using temporary inactivation, we confirmed that the BNST is not necessary for the acquisition of cued or contextual fear memory. Systemic administration of the SSRI citalopram prior to fear conditioning led to an upregulation of the immediate early gene Arc (activity-regulated cytoskeleton-associated protein) in the oval nucleus of the BNST, and a majority of these neurons expressed the 5-HT2C receptor. Finally, local infusions of a 5-HT2C receptor antagonist directly into the oval nucleus of the BNST prevented the fear memoryenhancing effects of citalopram. These findings highlight the ability of the BNST circuitry to be recruited into gating fear and anxiety-like behaviors.
Introduction
Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed to treat anxiety disorders and depression (Kent, Coplan, & Gorman, 1998; van der Kolk et al., 1994) . However, they paradoxically increase anxiety in humans when they are given acutely (Mir & Taylor, 1997) , and can increase the risk of suicidal ideation (Teicher, Glod, & Cole, 1990) . Rodent models of anxiety including the elevated plus maze, social interaction task and novelty suppressed feeding task reveal a similar anxiogenic effect of acute SSRI administration (Bodnoff, Suranyi-Cadotte, Quirion, & Meaney, 1989; Dekeyne, Denorme, Monneyron, & Millan, 2000; Griebel, Cohen, Perrault, & Sanger, 1999) .
Previous research has revealed that acute SSRI administration prior to fear conditioning enhances the consolidation of fear memories (Burghardt, Sullivan, McEwen, Gorman, & LeDoux, 2004; Ravinder, Burghardt, Brodsky, Bauer, & Chattarji, 2013) . One advantage of using fear conditioning to investigate the actions of SSRIs is that it is a model of emotional learning for which the underlying neural circuitry has been characterized in great detail (Johansen, Cain, Ostroff, & LeDoux, 2011; Orsini & Maren, 2012; Pape & Pare, 2010) . Fear conditioning engages fear circuits as well as mechanisms involved in learning and memory. Moreover, many anxiety disorders in humans can be characterized as abnormalities in the acquisition or extinction of conditioned fear (Grillon, 2002; Milad et al., 2008) .
The enhancing effects of SSRIs on fear conditioning appear to involve neural activity within the bed nucleus of the stria terminalis (BNST), as systemic injections or intra-BNST infusions of the SSRI fluoxetine potentiate fear learning (Ravinder et al., 2013) . Systemic administration of SSRIs also lead to upregulation of the immediate early gene Arc (activity-regulated cytoskeleton associated protein) in the oval nucleus of the BNST (BNSTov; Ravinder et al., 2013) . The BNSTov, which is a subregion of the anterolateral BNST (BNST-AL), is one of a dozen defined cell groups within the BNST (Alheid, 2003) . In general, the BNST has been implicated in processing both adaptive and pathological anxiety, with the majority of studies focusing on its contribution to an animal's response to unpredictable stressful events and anxiety (Alheid, 2003; Dunn & Williams, 1995) .
Lesions of the BNST do not interfere with fear conditioning (LeDoux, Iwata, Cicchetti, & Reis, 1988; Sullivan et al., 2004) . Instead, they disrupt the expression of longer ''anxiety-like" states (Walker, Toufexis, & Davis, 2003) . This has led to the idea that short duration cues (such as a 30 s tone) recruit amygdalar circuits, whereas long-duration cues, including contextual cues, recruit the BNST (Lee & Davis, 1997; Walker, Miles, & Davis, 2009 ). However, there is also evidence that BNST activity can modulate fear
